DENTSPLY SIRONA (XRAY) Set to Release Earnings on Thursday

Key Points

• DENTSPLY SIRONA is scheduled to report Q3 2026 earnings after the market closes on November 5, with analysts expecting $0.3117 in EPS and $861.65 million in revenue. Full-year 2026 guidance is $1.40–$1.50 EPS.
• The company’s previous quarter beat expectations, reporting $0.52 EPS and $898 million in revenue, though revenue declined 4.1% year over year and net margin was negative.
• XRAY shares opened at $9.44, near their one-year low, while analysts maintain a consensus “Hold” rating and a $12.62 price target after several recent target reductions.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect DENTSPLY SIRONA to announce earnings of $0.3117 per share and revenue of $861.65 million for the quarter. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Parties can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The company had revenue of $898.00 million for the quarter, compared to analysts' expectations of $889.93 million. During the same period last year, the firm posted $0.52 earnings per share. DENTSPLY SIRONA's revenue was down 4.1% compared to the same quarter last year. On average, analysts expect DENTSPLY SIRONA to post $1.39 EPS for the current fiscal year and $1.49 EPS for the next fiscal year.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $9.44 on Thursday. DENTSPLY SIRONA has a one year low of $8.32 and a one year high of $14.76. The stock has a 50-day moving average of $9.75 and a 200 day moving average of $11.37. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -3.43, a PEG ratio of 1.20 and a beta of 0.87. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.07 and a current ratio of 1.63.

Analyst Upgrades and Downgrades

XRAY has been the topic of a number of recent analyst reports. Barrington Research dropped their price target on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Monday. Leerink Partners cut their target price on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a "market perform" rating for the company in a research report on Wednesday, October 14th. Mizuho decreased their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, October 22nd. BMO Capital Markets decreased their target price on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating for the company in a research note on Thursday, September 17th. Finally, Barclays increased their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an "underweight" rating in a report on Monday, August 24th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $12.62.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.